The FDA committee reviewing 7 peptides on July 23 (BPC-157, TB-500, Epitalon + more) has recommended ZERO of its first twelve substance reviews for approval.
Twelve to nothing.
The longevity industry is pricing in a 70% yes. 馃У
Compounded
@Compoundedhq
An anonymous brief on how cash-pay healthcare gets built. Stack maps 路 regulatory analysis 路 corpus quarterlies. Bi-weekly. Faceless.
Joined May 2026
